Interactions in binding site of drug resistant protease
Patient ID 6652 6665 6670 6671 6674 6678 6685 6686 6687 6689 6691 6693 6696 6706 19255
Conserved residues in Interactions observed in crystals (%) 52 52 42 52 52 52 52 52 52 52 52 52 52 52 36
  ASP 25A ASP 25A ASP 25A ASP 25A ASP 25A ASP 25A ASP 25A ASP 25A ASP 25A ASP 25A ASP 25A ASP 25A ASP 25A ASP 25A ASP 25A
  ASP 25B ASP 25B ASP 25B ASP 25B ASP 25B ASP 25B ASP 25B ASP 25B ASP 25B ASP 25B ASP 25B ASP 25B ASP 25B ASP 25B ASP 25B
  ASP 29A ASP 29A ASP 29A ASP 29A ASP 29A ASP 29A ASP 29A ASP 29A ASP 29A ASP 29A ASP 29A ASP 29A ASP 29A ASP 29A ASP 29A
  ASP 29B ASP 29B ASP 29B ASP 29B ASP 29B ASP 29B ASP 29B ASP 29B ASP 29B ASP 29B ASP 29B ASP 29B ASP 29B ASP 29B ASP 29B
  ASP 30A ASP 30A ASP 30A ASP 30A ASP 30A ASP 30A ASP 30A ASP 30A ASP 30A ASP 30A ASP 30A ASP 30A ASP 30A ASP 30A ASP 30A
  ASP 30B ASP 30B ASP 30B ASP 30B ASP 30B ASP 30B ASP 30B ASP 30B ASP 30B ASP 30B ASP 30B ASP 30B ASP 30B ASP 30B ASP 30B
  GLY 27A GLY 27A GLY 27A GLY 27A GLY 27A GLY 27A GLY 27A GLY 27A GLY 27A GLY 27A GLY 27A GLY 27A GLY 27A GLY 27A GLY 27A
  GLY 27B GLY 27B GLY 27B GLY 27B GLY 27B GLY 27B GLY 27B GLY 27B GLY 27B GLY 27B GLY 27B GLY 27B GLY 27B GLY 27B GLY 27B
  GLY 48A GLY 48A ILE 50A GLY 48A GLY 48A GLY 48A ILE 50A GLY 48A GLY 48A GLY 48A GLY 48A GLY 48A GLY 48A GLY 48A GLY 48A
  GLY 48B GLY 48B ILE 50B GLY 48B GLY 48B GLY 48B ILE 50B GLY 48B GLY 48B GLY 48B GLY 48B GLY 48B GLY 48B GLY 48B GLY 48B
  ILE 50A ILE 50A     ILE 50A ILE 50A ILE 50A         ILE 50A ILE 50A ILE 50A ILE 50A ILE 50A ILE 50A ILE 50A
  ILE 50B ILE 50B     ILE 50B ILE 50B ILE 50B         ILE 50B ILE 50B ILE 50B ILE 50B ILE 50B ILE 50B ILE 50B
                                                             
Table 10: Residues in interaction with the drug of treatment 2 (second treatment to overcome drug resistance) are listed. Those highlighted in yellow are part of the critical set (see Table, Supplemental Digital Content 8, which shows the critical residues involved in ARV interactions and characterized in the crystal HIV-1 proteases from HIV-PDI database). These residues are no longer involved in the interaction with the drug of treatment 1 (Treatment which produce drug resistance).